UBS Group’s MediciNova MNOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $304K | Sell |
222,200
-3,461
| -2% | -$5.24K | ﹤0.01% | 6386 |
|
|
2025
Q4 | $296K | Buy |
225,661
+3,394
| +2% | +$4.68K | ﹤0.01% | 6368 |
|
|
2025
Q3 | $282K | Buy |
222,267
+67
| +0% | +$87 | ﹤0.01% | 6467 |
|
|
2025
Q2 | $291K | Hold |
222,200
| – | – | ﹤0.01% | 6457 |
|
|
2025
Q1 | $324K | Sell |
222,200
-538
| -0.2% | -$952 | ﹤0.01% | 6184 |
|
|
2024
Q4 | $468K | Sell |
222,738
-82,751
| -27% | -$162K | ﹤0.01% | 5897 |
|
|
2024
Q3 | $642K | Buy |
305,489
+305,340
| +204,926% | +$452K | ﹤0.01% | 5030 |
|
|
2024
Q2 | $215 | Sell |
149
-2,363
| -94% | -$3.31K | ﹤0.01% | 9070 |
|
|
2024
Q1 | $3.64K | Buy |
+2,512
| New | +$3.57K | ﹤0.01% | 7715 |
|
|
2023
Q3 | – | Sell |
-91,828
| Closed | -$211K | – | 9781 |
|
|
2023
Q2 | $211K | Sell |
91,828
-53,404
| -37% | -$118K | ﹤0.01% | 5442 |
|
|
2023
Q1 | $314K | Sell |
145,232
-9,242
| -6% | -$21.2K | ﹤0.01% | 5048 |
|
|
2022
Q4 | $317K | Sell |
154,474
-29,554
| -16% | -$65.3K | ﹤0.01% | 5071 |
|
|
2022
Q3 | $399K | Hold |
184,028
| – | – | ﹤0.01% | 4535 |
|
|
2022
Q2 | $466K | Sell |
184,028
-5,912
| -3% | -$15.4K | ﹤0.01% | 4310 |
|
|
2022
Q1 | $506K | Buy |
189,940
+738
| +0.4% | +$1.81K | ﹤0.01% | 4681 |
|
|
2021
Q4 | $507K | Buy |
189,202
+169,930
| +882% | +$568K | ﹤0.01% | 4970 |
|
|
2021
Q3 | $73K | Buy |
19,272
+9,437
| +96% | +$35.9K | ﹤0.01% | 6056 |
|
|
2021
Q2 | $42K | Sell |
9,835
-10,102
| -51% | -$43.5K | ﹤0.01% | 6594 |
|
|
2021
Q1 | $100K | Buy |
19,937
+11,080
| +125% | +$64.5K | ﹤0.01% | 5963 |
|
|
2020
Q4 | $47K | Buy |
8,857
+1,990
| +29% | +$11.4K | ﹤0.01% | 6245 |
|
|
2020
Q3 | $36K | Sell |
6,867
-8,663
| -56% | -$50K | ﹤0.01% | 5864 |
|
|
2020
Q2 | $84K | Sell |
15,530
-10,937
| -41% | -$58K | ﹤0.01% | 5434 |
|
|
2020
Q1 | $98K | Sell |
26,467
-26,951
| -50% | -$140K | ﹤0.01% | 5312 |
|
|
2019
Q4 | $360K | Buy |
53,418
+27,703
| +108% | +$208K | ﹤0.01% | 5134 |
|
|
2019
Q3 | $205K | Buy |
25,715
+24,440
| +1,917% | +$218K | ﹤0.01% | 5233 |
|
|
2019
Q2 | $13K | Sell |
1,275
-2,159
| -63% | -$22.8K | ﹤0.01% | 6897 |
|
|
2019
Q1 | $29K | Sell |
3,434
-2,646
| -44% | -$23.1K | ﹤0.01% | 5974 |
|
|
2018
Q4 | $50K | Sell |
6,080
-4,802
| -44% | -$47.9K | ﹤0.01% | 6086 |
|
|
2018
Q3 | $136K | Buy |
10,882
+5,906
| +119% | +$59.3K | ﹤0.01% | 5333 |
|
|
2018
Q2 | $40K | Sell |
4,976
-2,191
| -31% | -$22.7K | ﹤0.01% | 6167 |
|
|
2018
Q1 | $73K | Sell |
7,167
-2,376
| -25% | -$23.7K | ﹤0.01% | 5443 |
|
|
2017
Q4 | $62K | Buy |
9,543
+963
| +11% | +$6.39K | ﹤0.01% | 5681 |
|
|
2017
Q3 | $55K | Sell |
8,580
-5,420
| -39% | -$28.8K | ﹤0.01% | 5727 |
|
|
2017
Q2 | $74K | Sell |
14,000
-2,368
| -14% | -$13.3K | ﹤0.01% | 5375 |
|
|
2017
Q1 | $98K | Buy |
16,368
+14,395
| +730% | +$86.7K | ﹤0.01% | 5091 |
|
|
2016
Q4 | $12K | Sell |
1,973
-1,167
| -37% | -$8.22K | ﹤0.01% | 6814 |
|
|
2016
Q3 | $24K | Buy |
3,140
+2,734
| +673% | +$18.4K | ﹤0.01% | 6151 |
|
|
2016
Q2 | $3K | Sell |
406
-51,134
| -99% | -$370K | ﹤0.01% | 7332 |
|
|
2016
Q1 | $378K | Buy |
51,540
+51,528
| +429,400% | +$255K | ﹤0.01% | 3988 |
|
|
2015
Q4 | $0 | Hold |
12
| – | – | ﹤0.01% | 8484 |
|
|
2015
Q3 | $0 | Sell |
12
-1,486
| -99% | -$5.07K | ﹤0.01% | 8536 |
|
|
2015
Q2 | $6K | Buy |
+1,498
| New | +$5.92K | ﹤0.01% | 7789 |
|
|
2015
Q1 | – | Sell |
-50
| Closed | – | – | 9132 |
|
|
2014
Q4 | $0 | Buy |
+50
| New | +$169 | ﹤0.01% | 9681 |
|
Other funds holding MNOV
EWM
VCM
VFT
UBS Group's MNOV Position: Q1 2026 in Review
UBS Group reduced its MediciNova (MNOV) stake by 1.5% in Q1 2026, selling an estimated $5.24K and leaving 222,200 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #6386.
UBS Group first reported a position in MNOV in Q4 2014 and has held it in 43 quarters since. The position peaked at $642K in Q3 2024. 30 funds tracked by Wall St. Rank hold MNOV as of Q1 2026.
- UBS Group held 222,200 shares of MediciNova worth $304K as of Q1 2026.
- UBS Group sold 3,461 MediciNova shares in Q1 2026, an estimated $5.24K.
- MediciNova made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6386 holding.
- UBS Group first reported a position in MediciNova in Q4 2014 and has held it in 43 quarters since.
- UBS Group's MediciNova position peaked at $642K in Q3 2024.
- 30 funds tracked by Wall St. Rank held MediciNova as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.